GlassScriptPhysician profile
Heather R Baum
NPI 1396269742
$3,454.40
in general payments reported to CMS, 2019-2025
23 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $700 · 2023: $751 · 2024: $1,253 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $465.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $461.18 | 2022-2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $248.87 | 2022-2023 | |
| Glaxosmithkline, LLC. | $247.08 | 2023-2024 | Bexsero, Arexvy |
| Abbvie INC. | $224.39 | 2023-2024 | |
| Axsome Therapeutics, INC. | $195.26 | 2025 | Auvelity |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Amgen INC. | $145.79 | 2024 | |
| Biomerieux INC | $143.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Phathom Pharmaceuticals, INC. | $126.20 | 2024 | Voquezna |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2022 | |
| Genzyme Corporation | $122.92 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $112.21 | 2024 | Airsupra |
| Averitas Pharma INC. | $96.33 | 2024 | Qutenza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $95.60 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.04 | 2022 | |
| Neurelis, INC. | $77.57 | 2023 | Valtoco |
| Edwards Lifesciences Corporation | $76.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $68.58 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $39.64 | 2022 | |
| Currax Pharmaceuticals LLC | $17.94 | 2022 | |
| Intra-Sana Laboratories | $6.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.